Obstructive Sleep Apnea in Idiopathic Intracranial Hypertension: Comparison with Matched Population Data (P07.261)

Abstract

Objective: To compare the prevalence and severity of obstructive sleep apnea (OSA) in idiopathic intracranial hypertension (IIH) patients with the prevalence and severity from matched population data. Background Patients with IIH frequently have coexisting OSA. However, it is unclear if the prevalence and severity of OSA is greater in IIH patients than would be expected given their other risk factors for OSA (e.g., obesity). Design/Methods: We included patients with a new diagnosis of IIH who satisfied modified Dandy criteria and underwent overnight polysomnography. We collected demographic data, anthropometric data, and the apnea-hypopnea index (AHI) from polysomnography. We also calculated the expected AHI for our patients, based on their age, sex, race, BMI, and menopausal status, using a model derived from 1741 randomly-sampled members of the general population with overnight in-lab polysomnography scored using similar criteria. We compared the obtained AHI values to those predicted by the model using a paired t-test. Our study had 80% power to detect a 10 unit change in AHI at α = 0.05. Results: We included 24 IIH patients, of which 20 were female (83.3%), 13 were Caucasian (54.2%), and 11 were African-American (45.8%). Patient age ranged from 16-54 yrs (median = 32 yrs; mean±SD = 32±10 yrs). Body mass index ranged from 27.3-45.9 (median = 39.5; mean±SD = 38.1±5.3). AHI from the sleep studies ranged from 0-63.3 (median = 3.3; mean±SD = 9.4±15.8). Predicted AHI ranged from 2.1-14.5 (median = 5.4; mean±SD = 5.9±3.0). The AHIs from the sleep studies were not significantly different from those predicted by the population-derived model (p = 0.14). Conclusions: The prevalence and severity of OSA in IIH patients is no more than would be expected for their age, sex, race, and BMI. It remains unclear if the presence or treatment of coexisting OSA influences the clinical course of IIH. Supported by: In part by a departmental grant (Department of Ophthalmology) from Research to Prevent Blindness, Inc., New York, by core grant P30-EY06360 (Department of Ophthalmology), and by K23-EY019341 (Dr. Bruce). Dr. Newman is a recipient of the Research to Prevent Blindness Lew R. Wasserman Merit Award. Disclosure: Dr. Thurtell has nothing to disclose. Dr. Trotti has nothing to disclose. Dr. Bixler has nothing to disclose. Dr. Rye has received personal compensation for activities with GlaxoSmithKline, Boehringer Ingelheim Pharmaceuticals, UCB Pharma, and Jazz Pharmaceuticals as a consultant, advisor, or speaker. Dr. Bliwise has received personal compensation for activities with Ferring Pharmaceuticals as a consultant. Dr. Newman has received personal compensation for activities with Biogen Idec. Dr. Biousse has nothing to disclose. Dr. Bruce has nothing to disclose.